VIM and breast neoplasm: When examining the NEDD9 and mesenchymal markers, such as Vimentin and Fibronectin in 32 aggressive breast tumors, we found that positive expression of NEDD9 was associated significantly with the expression of Vimentin and Fibronectin (Fig. 5), implicating that NEDD9 may play a role in EMT in vivo in aggressive breast tumors.